BNP Paribas Financial Markets
LRMR icon

BNP Paribas Financial Markets’s Larimar Therapeutics LRMR Stock Holding History

BNP Paribas Financial Markets’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.2K Sell
10,886
-1,340
-11% -$5.32K ﹤0.01% 5089
2026
Q1 		$55K Sell
12,226
-327
-3% -$1.31K ﹤0.01% 4642
2025
Q4 		$47.8K Buy
12,553
+2,407
+24% +$9.36K ﹤0.01% 4706
2025
Q3 		$32.8K Buy
10,146
+4,376
+76% +$16.4K ﹤0.01% 4771
2025
Q2 		$16.7K Buy
5,770
+1,852
+47% +$4.29K ﹤0.01% 4680
2025
Q1 		$8.42K Sell
3,918
-2,547
-39% -$8.05K ﹤0.01% 4761
2024
Q4 		$25K Buy
+6,465
New +$42.7K ﹤0.01% 4668
2020
Q2 		– Sell
-7
Closed -$67 – 4351
2020
Q1 		$67 Hold
7
– – ﹤0.01% 4231
2019
Q4 		$97 Sell
7
-303
-98% -$2.9K ﹤0.01% 4332
2019
Q3 		$2.75K Hold
310
– – ﹤0.01% 4337
2019
Q2 		$4.42K Sell
310
-245
-44% -$6.53K ﹤0.01% 4257
2019
Q1 		$18.2K Buy
555
+531
+2,213% +$27.2K ﹤0.01% 3922
2018
Q4 		$1.43K Sell
24
-38
-61% -$3.75K ﹤0.01% 3865
2018
Q3 		$8.72K Sell
62
-1
-2% -$121 ﹤0.01% 3802
2018
Q2 		$7.7K Buy
63
+62
+6,200% +$5.27K ﹤0.01% 3905
2018
Q1 		$45 Hold
1
– – ﹤0.01% 4160
2017
Q4 		$28 Hold
1
– – ﹤0.01% 4172
2017
Q3 		$21 Hold
1
– – ﹤0.01% 4189
2017
Q2 		$21 Sell
1
-15
-94% -$767 ﹤0.01% 4211
2017
Q1 		$909 Sell
16
-18
-53% -$894 ﹤0.01% 3719
2016
Q4 		$1.29K Sell
34
-96
-74% -$3.89K ﹤0.01% 3993
2016
Q3 		$5.14K Buy
130
+55
+73% +$2.5K ﹤0.01% 3379
2016
Q2 		$5.42K Buy
75
+32
+74% +$2.53K ﹤0.01% 3238
2016
Q1 		$3.44K Sell
43
-291
-87% -$23K ﹤0.01% 2329
2015
Q4 		$25.2K Buy
334
+41
+14% +$6.59K ﹤0.01% 3211
2015
Q3 		$112K Buy
293
+12
+4% +$5.41K ﹤0.01% 2321
2015
Q2 		$117K Buy
281
+185
+193% +$77.4K ﹤0.01% 1998
2015
Q1 		$45.4K Buy
+96
New +$45.6K ﹤0.01% 1967

Other funds holding LRMR

BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

BNP Paribas Financial Markets's LRMR Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Larimar Therapeutics (LRMR) stake by 11% in Q2 2026, selling an estimated $5.32K and leaving 10,886 shares worth $33.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5089.

BNP Paribas Financial Markets first reported a position in LRMR in Q1 2015 and has held it in 28 quarters since. The position peaked at $117K in Q2 2015. 150 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • BNP Paribas Financial Markets held 10,886 shares of Larimar Therapeutics worth $33.2K as of Q2 2026.
  • BNP Paribas Financial Markets sold 1,340 Larimar Therapeutics shares in Q2 2026, an estimated $5.32K.
  • Larimar Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5089 holding.
  • BNP Paribas Financial Markets first reported a position in Larimar Therapeutics in Q1 2015 and has held it in 28 quarters since.
  • BNP Paribas Financial Markets's Larimar Therapeutics position peaked at $117K in Q2 2015.
  • 150 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.